CClinicalTrials.gg
CompletedNCT06736366Co10_2024Updated Dec 5, 2025

Study With Two Coenzyme Q10 Products

An interventional study of Dietary supplement - Active comparator and Dietary supplement - Experimental product in Coenzyme Q Deficiency, sponsored by University of Primorska. Completed at 1 site in Slovenia. Open to participants aged 50 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-05.

Sponsored by University of Primorska · Not applicable, Interventional, and Screening

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
50 Years to 65 Years
Sex
All
01

Study summary

The randomized, open-label, two period crossover single-dose bioavailability study with two coenzyme Q10 products

Read the detailed description

The randomized, open-label, two period crossover single-dose bioavailability study with two coenzyme Q10 products will include 35 subjects who will test two different coenzyme Q10 products. Plasma concentration of coenzyme Q10 will be measured.

02

Conditions studied

  • Coenzyme Q Deficiency

Keywords

  • single dose bioavailability
  • Coenzyme Q10
03

In context

Lead sponsor

University of Primorska is the lead sponsor of 53 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • subject informed consent form
  • aged between 50 and 65 years old
  • body mass for women 70± 5 kg and for men 85± 5 kg
  • non-smoking
  • healthy, without cardio-vascular diseases, diabetes, neurodegenerative diseases
  • absence of any prescribed medication during the study
  • willing to avoid a consumption of any food supplements at least 2 weeks before and during the study

Exclusion criteria

Exclusion Criteria:

  • cardio-vascular diseases, diabetes, neurodegenerative diseases, gastrointestinal disorders, pregnancy, breast-feeding
  • intake of any food supplements within two week of the beginning of the study
  • drug or alcohol abuse
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
25 participants (actual)

Study arms

  • Active comparator
    Coenzyme Q10 (ubiquinone)

    Synonyms: Maltodextrin, capsule (HPMC - hydroxypropyl methyl cellulose), coenzyme Q10 (ubiquinone); Dosage: 2 capsules, total 100 mg Co-Q10

    Dietary Supplement: Dietary supplement - Experimental product

  • Experimental
    BMT® coenzyme Q10

    Maltodextrin, BMT® coenzyme Q10 \[maltodextrin, coenzyme Q10 (ubiquinone), stabiliser (gum arabic), corn starch, olive oil, anti-caking agent (silicon dioxide), acidity regulators (acetic acid, citric acid)\], capsule (HPMC - hydroxypropyl methyl cellulose); Dosage: 2 capsules, total 100 mg Co-Q10

    Dietary Supplement: Dietary supplement - Active comparator

Interventions

  • Dietary supplementDietary supplement - Active comparator

    Single dose intervention with Standard product Coenzyme Q10 (ubiquinone); 2 capsules - 100 mg total coenzyme Q10

  • Dietary supplementDietary supplement - Experimental product

    Single dose intervention with Experimental product; BMT® coenzyme Q10; 2 capsules - 100 mg total coenzyme Q10

06

What researchers measure

Primary outcomes

  1. Plasma levels of Coenzyme Q10

    Plasma levels of Coenzyme Q10 will be measured by high-performance liquid chromatography (HPLC) with electrochemical detection and a post-analytical reducing column, using a Nanospace HPLC apparatus.

    Time frame: At Baseline

  2. Plasma levels of Coenzyme Q10

    Plasma levels of Coenzyme Q10 will be measured by high-performance liquid chromatography (HPLC) with electrochemical detection and a post-analytical reducing column, using a Nanospace HPLC apparatus.

    Time frame: Four hours after consumption

  3. Plasma levels of Coenzyme Q10

    Plasma levels of Coenzyme Q10 will be measured by high-performance liquid chromatography (HPLC) with electrochemical detection and a post-analytical reducing column, using a Nanospace HPLC apparatus.

    Time frame: Six hours after consumption

  4. Plasma levels of Coenzyme Q10

    Plasma levels of Coenzyme Q10 will be measured by high-performance liquid chromatography (HPLC) with electrochemical detection and a post-analytical reducing column, using a Nanospace HPLC apparatus.

    Time frame: Twelve hours after consumption

  5. Plasma levels of Coenzyme Q10

    Plasma levels of Coenzyme Q10 will be measured by high-performance liquid chromatography (HPLC) with electrochemical detection and a post-analytical reducing column, using a Nanospace HPLC apparatus.

    Time frame: Twenty-four hours after consumption

  6. Plasma levels of Coenzyme Q10

    Plasma levels of Coenzyme Q10 will be measured by high-performance liquid chromatography (HPLC) with electrochemical detection and a post-analytical reducing column, using a Nanospace HPLC apparatus.

    Time frame: Forthy-eight hours after consumption

07

Study locations

1 site
  • University of Primorska, Faculty of Health Sciences
    Izola, Municipality of Izola 6310, Slovenia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06736366
Lead sponsor
University of Primorska
Collaborators
Biostile, QFarm s.r.l.
Responsible party
Zala Jenko Praznikar (Associate Professor, PhD, University of Primorska) — Principal investigator
First posted
Dec 16, 2024
Start date
Dec 5, 2024
Primary completion
Dec 16, 2024
Completion
Jun 30, 2025
Last update
Dec 5, 2025

Study contacts

Ana Petelin, phD
principal investigator · University of Primorska, Faculty of Health Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion